Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol.
We investigated the clinical response of chronic heart failure patients with beta(2)-adrenergic receptor Gln(27)-->Glu polymorphism treated for 6 months with carvedilol, a alpha/beta-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu(27)beta(2)-adrenergic receptor allele. There were however, no significant changes in patients with the Gln(27)beta(2)-adrenergic receptor variant.
FONDAP Center for Molecular Studies of the Cell, Faculty of Chemical and Pharmaceutical Sciences, P. Catholic University of Chile, Santiago, Chile.
Rodrigo
R
Troncoso
Francisco
F
Moraga
Mario
M
Chiong
Juan
J
Roldán
Roberto
R
Bravo
Rodrigo
R
Valenzuela
Guillermo
G
Díaz-Araya
Andrea
A
del Campo
Carlos
C
Sanhueza
Andrea
A
Rodriguez
José Luis
JL
Vukasovic
Rosemarie
R
Mellado
Douglas
D
Greig
Pablo F
PF
Castro
Sergio
S
Lavandero
D058672:Adrenergic beta-2 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002227:Carbazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077261:Carvedilol; D002908:Chronic Disease; D015536:Down-Regulation; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011412:Propanolamines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics*; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
D058672:Adrenergic beta-2 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D018343:Receptors, Adrenergic, beta-2; D000077261:Carvedilol; D008315:Malondialdehyde